期刊文献+

中晚期肺癌患者Nanog表达与GP方案化疗效果的关系 被引量:1

Relationship between effect of GP regimen prognostic significance and Nanog expression in advanced lung cancer
原文传递
导出
摘要 目的探讨中晚期(Ⅲ期和Ⅳ期)非小细胞肺癌(NSCLC)患者Nanog基因和蛋白的表达与GP方案化疗的疗效关系,并分析对生存期的影响。方法选择使用GP方案化疗的晚期NSCLC患者62例,对使用实时定量聚合酶链反应(qRT-PCR)和免疫组织化学两种方法均检测出Nanog阳性表达的肺癌患者进行GP方案治疗的效果进行对比,并对生存期的影响进行统计分析。结果62例中晚期NSCLC中,Nanog基因和蛋白表达呈阳性30例(48.4%),Nanog阳性表达患者的有效率与未表达的患者比较差异有统计学意义(x^2=0.872,P〈0.01)。完全缓解(CR)组的Nanog阳性表达明显低于部分缓解(PR)组和进展(PD)组,32例有效(CR+PR)患者中Nanog呈阳性表达9例(28.1%),阴性表达23例(71.9%)。而未显效的32例中Nanog呈阳性表达21例(70.0%),阴性表达9例(30.0%)。生存分析显示,Nanog阳性表达的患者5年生存期短于Nanog阴性表达的患者。结论Nanog表达增强可能导致NSCLC患者对GP方案化疗不敏感并导致5年生存期缩短,检测Nanog的表达可为临床制定NSCLC的个体化治疗方案提供依据,并对预测肿瘤的预后提供参考。 Objective To evaluate the correlation between the expression level of Nanog gene and clinical outcomes of GP regimen in the advanced non-small cell lung cancer (NSCLC). Methods 62 patients of NSCLC were treated by GP method, and the outcomes were investiged between Nanog positive and nagetive patients. The expression level of Nanong was evaluated by RT-PCR and immunohistology. Results 30 out of 62 patients (48.4 %) were Nanog positive, 9 patients (28.1%) were Nanog positive, and 23 out of 32 patients were Nanog negative (71.9 %) who have the positive effect (CR+PR). However, among 32 treatment nagetive cases, there were 21 cases (70.0 %) who were Nanog positive and 9 cases (30.0 %) were Nanog negatve. Survival analysis showed that 5-years lifetime of Nanog positive patients was shorter than Nanong nagetive patients. Conclusion Nanog overexpression decreases the sensitivity of GP regimen and lifetime of NSCLC patient. Nanog expression level may provide a useful factor for clinical treatment and prognosis of NSCLC patient.
出处 《肿瘤研究与临床》 CAS 2013年第9期609-611,共3页 Cancer Research and Clinic
基金 广西壮族自治区卫生厅计划课题(Z2011171)
关键词 非小细胞肺 NANOG 药物疗法 联合 治疗结果 Cancer, non-small cell lung Nanog Drug therapy, combination Trentment outcome
  • 相关文献

参考文献2

二级参考文献22

  • 1Liang H, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol, 2010, 79: 817- 824.
  • 2Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem pharmacol, 2008, 76: 582-588.
  • 3Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer, 2008, 123: 372-379.
  • 4Ambros V. The functions of animal microRNAs. Nature, 2004, 431 : 350-355.
  • 5Barrel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116:281-297.
  • 6Bushati N, Cohen SM. MicroRNA functions. Annu Rev Cell Dev Biol, 2007.23: 175-205.
  • 7Chan SP, Ramaswamy G, Choi EY, et al. Identification of specific let-7 microRNA binding complexes in Caenorhabditis elegans. RNA, 2008, 14: 2104-2114.
  • 8Bertino JR, Banerjee D, Mishra PJ. Pharmacogenom-ics of microRNA: a miRSNP towards individualized therapy. Pharmacogenomics, 2007, 8: 1625-1627.
  • 9Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, 2008, 27: 3845-3855.
  • 10Sorrentino A, Liu CG, Addario A, et al. Role of microRNAs in drug- resistant ovarian cancer ceils. Gynecol Oncol, 2005, 111: 478-486.

共引文献54

同被引文献17

引证文献1

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部